To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Despite the prevalence of cancer misinformation, exposure to it is not associated with greater fear of cancer recurrence or ...

Cardiovascular (CV) disease is a leading cause of death among patients with prostate cancer. | Cardiovascular (CV) disease is ...

Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks like pretzel. The tube straightens while it is inserted by catheter into the ...

Accordingly, it is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend. John Hopkins University was an early participant in the clinical ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 ...

Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s ...